Pancreatic beta cell antigens

Pancreatic beta cell antigens are a group of endogenous proteins expressed by the insulin-producing cells of the pancreatic islets that become the focus of autoimmune destruction in Type 1 Diabetes (T1D) (Atkinson et al., 2014, Lancet). The most prominent antigens include Insulin, Glutamic acid decarboxylase 65 (GAD65), Insulinoma-associated protein 2 (IA-2), and Zinc transporter 8 (ZnT8) (Pihoker et al., 2005, Diabetes Care). In individuals with a genetic predisposition, the immune system's loss of self-tolerance leads to the activation of autoreactive T cells and the production of autoantibodies against these specific proteins. This process results in the progressive loss of beta cell function and mass, eventually leading to clinical hyperglycemia (Insel et al., 2015, Diabetes Care). Therapeutic strategies targeting these antigens or the immune cells that recognize them, such as Teplizumab or GAD65-based vaccines, aim to preserve endogenous insulin secretion by halting the autoimmune attack (Herold et al., 2019, NEJM; Ludvigsson et al., 2012, NEJM). Consequently, these antigens serve as both critical biomarkers for disease prediction and primary focal points for the development of disease-modifying immunotherapies.

Other names

Islet cell autoantigensBeta-cell autoantigensType 1 diabetes autoantigensIslet cell antigens

Modulation of the autoimmune response through T-cell inhibition, B-cell depletion, or antigen-specific tolerance induction to preserve beta cell mass.